Unicycive Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €501.48M -2.1% €303.88M -3.6% 60.6% -0.0094 pp N/A N/A
    (estimated) €512.12M +0.0% €315.16M +2.7% 61.5% +0.016 pp N/A N/A
    (estimated) €512.00M +114.2% €306.86M +398.3% 59.9% +0.34 pp N/A N/A
    (estimated) €239.02M +46,840.7% €61.58M -398.0% 25.8% +41 pp N/A N/A
    (estimated) €509.19K +∞% -€20.66M -34.8% -4,057.6% -41 pp N/A N/A
    €0.00 -100.0% -€31.70M +20.2% N/A -€24.60M +56.0% N/A
    €582.55K -29.0% -€26.36M +69.1% -4,525.0% -26 pp -€15.77M +16.8% -2,706.8% -11 pp
    €820.75K +∞% -€15.59M +69.9% -1,899.5% -19 pp -€13.51M +172.7% -1,645.5% -16 pp
    €0.00 +NaN% -€9.18M +323.9% N/A -€4.95M +293.3% N/A
    €0.00 +NaN% -€2.16M +8.9% N/A -€1.26M +24.1% N/A
    €0.00 +NaN% -€1.99M +105.7% N/A -€1.01M +51.7% N/A
    €0.00 -€966.60K N/A -€668.85K N/A

    Notifications